**
As the popularity of GLP-1 medications like Ozempic, Wegovy, and Mounjaro continues to rise among individuals seeking weight loss and diabetes management, healthcare professionals are increasingly alerting patients to potential risks. A troubling trend has emerged: some users are developing unrecognised eating disorders linked to the powerful appetite-suppressing properties of these drugs. Experts are sounding alarms about a condition dubbed “agonorexia,” which may have serious implications for mental and physical health.
Unpacking Agonorexia: A New Form of Disordered Eating
Brad Smith, chief medical officer at The Emily Program—a national organisation focused on treating eating disorders—has described agonorexia as a dangerous fixation on food and weight loss triggered by GLP-1 medications. This new disorder appears distinct from traditional eating disorders such as anorexia and bulimia, presenting unique challenges for both patients and healthcare providers.
“We’ve encountered individuals who, after being prescribed these medications, find themselves slipping back into old eating disorder patterns,” Smith stated. “Even more concerning, some develop disordered eating behaviours despite having no previous history of eating disorders.” This alarming trend has raised questions about the adequacy of current medical screenings for those prescribed these medications.
The Medical Community’s Response
While the appetite-suppressing effectiveness of GLP-1 drugs is well-documented, research connecting these medications to new eating disorders remains limited. The National Association of Anorexia Nervosa and Associated Disorders emphasises that GLP-1 medications are not FDA-approved for treating any form of eating disorder, including binge eating disorder.
Despite the lack of formal recognition, healthcare professionals are increasingly witnessing patients exhibit signs of disordered eating, characterised by restrictive dietary habits that heighten the risk of developing full-blown eating disorders. “These medications are prescribed at doses significantly higher than those used for diabetes treatment, which can have far-reaching effects on a person’s eating behaviours,” cautioned Dr. Rebecca Boswell, Director at Penn Medicine Princeton Centre for Eating Disorders.
Weight Stigma and Its Role in Eating Disorders
The intersection of weight stigma and the use of GLP-1 medications cannot be overlooked. Individuals with higher body weights are often more likely to be recommended weight-loss interventions, which can exacerbate unhealthy thought patterns surrounding food and body image.
“It’s concerning that these medications are prescribed at doses two to five times higher than necessary for diabetes treatment,” Dr. Boswell noted during her presentation at the Eating Disorders Research Society Conference in Sitges, Spain. She warned that the long-term sustainability of such treatments is uncertain, especially given the psychological vulnerabilities that may accompany significant weight loss.
The Need for Comprehensive Research
As the medical community grapples with the implications of GLP-1 medications, experts stress the urgent need for comprehensive research on their effects, particularly among individuals with pre-existing vulnerabilities to eating disorders. Current studies are often limited in scope and duration, leaving many questions unanswered regarding the long-term impact of these medications on eating behaviours.
According to the National Eating Disorder Association, while there are indications that GLP-1 medications may reduce binge-eating episodes in some patients, the evidence is far from conclusive. “Recovery from eating disorders relies on consistent eating patterns and body acceptance, yet the impact of GLP-1 medications on these recovery strategies remains largely unknown,” the association stated.
Why it Matters
The rise of GLP-1 medications as a popular weight-loss solution brings with it a pressing need for awareness and education around their potential risks. As healthcare providers increasingly observe new forms of disordered eating, it is crucial that patients are informed of the psychological implications associated with these treatments. Understanding the complex relationship between appetite suppression and disordered eating behaviours could be key to improving patient outcomes and safeguarding mental health in an era where body image and weight loss continue to dominate societal discourse.